Ambar Andrade
Advanced Heart Failure and Transplant Cardiology · Oak Lawn, ILNPI 1174751978
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,750 of the $35,344 with a category attached, or 70.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 66.7% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $16,888, 3.9 times the $4,386 reported in 2019.
Across 315 payments — averaging $112.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24K
- Abbott$5K
- Alnylam Pharmaceuticals Inc.$4K
- Abiomed$2K
- Medtronic$551
- Novartis$137
- plus $414 from 12 others
What the payments were for
- Speaking & faculty fees$24,75070%
- Travel & lodging$2,6788%
- Food & beverage$7,89222%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 39 | $23,580 |
| Abbott | 203 | $4,994 |
| Alnylam Pharmaceuticals Inc. | 8 | $4,011 |
| Abiomed | 12 | $1,657 |
| Medtronic(2 entities) | 25 | $551 |
| Novartis | 7 | $137 |
| AstraZeneca | 3 | $62 |
| Boehringer Ingelheim | 2 | $56 |
| Bridgebio Pharma, Inc. | 3 | $53 |
| Novo Nordisk | 3 | $51 |
| Kestra Medical Technology Services, Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Bayer | 1 | $26 |
| Daxor Corporation | 1 | $22 |
| Pfizer | 1 | $21 |
| Edwards Lifesciences | 1 | $18 |
| Picard Medical Inc. | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$23,048
- AMVUTTRA$3,750
- Impella$1,370
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$766
- CARDIOMEMS$138
- HeartWare HVAD$114
- HeartMate 3 Left Ventricular Dev$112
- ONPATTRO$112
How this compares
$35,344 in reported general payments places this provider in the 65th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 40 | $38,426 |
| FarxigaDapagliflozin Propanediol | 31 | $27,464 |
| JardianceEmpagliflozin | 25 | $18,150 |
| EliquisApixaban | 11 | $13,942 |
| Metoprolol Succinate | 43 | $792 |
| Spironolactone | 68 | $687 |
| Torsemide | 14 | $502 |
| Atorvastatin Calcium | 17 | $155 |
| Furosemide | 30 | $100 |
| Carvedilol | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $137 | $38,42640 claims |
| AstraZenecaFarxiga | $62 | $27,46431 claims |
| Boehringer IngelheimJardiance | $56 | $18,15025 claims |
| PfizerEliquis | $21 | $13,94211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Oak Lawn
- Muhyaldee DiaOak Lawn$125K
- Sunil PauwaaOak Lawn$62K
- William CottsOak Lawn$8K
- Vinh ChauOak Lawn$7K
- Christopher SciamannaOak Lawn$930
- Maria Rosa CostanzoNaperville$716K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.